Pharmaceutical Pipeline

Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration as of July 21, 2021

Newly Advanced

6 of 53 Total Indications

Cardiovascular and Metabolism

Neuroscience

Oncology

This information is accurate as of the date hereof to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. (2) aprocitentan developed in collaboration with Idorsia; (3) XARELTO co-developed with Bayer HealthCare; (5) DARZALEX licensed from Genmab A/S; (6) IMBRUVICA developed in collaboration with Pharmacyclics, LLC, an AbbVie company; (7) BALVERSA discovered in collaboration with Astex Pharmaceuticals, Inc.; (8) Niraparib licensed from Tesaro; (9) BCMA CAR-T licensed from Legend Biotech; (10) Monovalent Ebola Vaccine developed in collaboration with Bavarian Nordic A/S, and MVA-BN-Filo® is licensed-in from Bavarian Nordic A/S; (11) DUOBODY platform licensed from Genmab relates to several bispecific antibody programs (Amivantamab, Teclistamab , Talquetamab);

Pharmaceutical Pipeline

Selected Pharmaceuticals in Late Stage U.S. and E.U. Development or Registration as of July 21, 2021

Cardiovascular and Metabolism

XARELTO (rivaroxaban)

Neuroscience

PONVORY (ponesimod)

Oncology

ciltacabtagene autoleucel (BCMA CAR-T)

DARZALEX (daratumumab)

DARZALEX (daratumumab)

RYBREVANT (amivantamab)